Loading...
REGN logo
REGN
Regeneron Pharmaceuticals

Dupixent And EYLEA Will Seize Expanding Global Markets

Published
08 Apr 25
Updated
07 May 25
AnalystHighTarget's Fair Value
US$890.00
32.6% undervalued intrinsic discount
10 Sep
US$600.00
Loading
1Y
-40.9%
7D
8.0%

Author's Valuation

US$89032.6% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates4

Shared on07 May 25
Fair value Decreased 21%

Read more

Shared on30 Apr 25
Fair value Decreased 0.14%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 9.25%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25
Fair value Increased 9.37%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more